Aligos Therapeutics (ALGS) Set to Announce Quarterly Earnings on Wednesday

Aligos Therapeutics (NASDAQ:ALGS) will be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Aligos Therapeutics to post earnings of ($2.15) per share for the quarter.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The firm had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same quarter last year, the firm earned ($10.75) earnings per share. On average, analysts expect Aligos Therapeutics to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Aligos Therapeutics Trading Down 2.4 %

NASDAQ ALGS opened at $9.55 on Monday. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $30.00. The company has a 50 day moving average of $10.14 and a 200-day moving average of $12.87. The firm has a market cap of $30.56 million, a price-to-earnings ratio of -0.47 and a beta of 2.11.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a report on Wednesday, October 23rd.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).